Emergent BioSolutions Inc. (EBS)
NYSE: EBS · IEX Real-Time Price · USD
11.20
-0.23 (-2.01%)
At close: Jul 19, 2024, 4:00 PM
11.10
-0.10 (-0.89%)
Pre-market: Jul 22, 2024, 7:37 AM EDT
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $1.19B in the twelve months ending March 31, 2024, with 21.32% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $300.40M with 82.84% year-over-year growth. In the year 2023, Emergent BioSolutions had annual revenue of $1.05B.
Revenue (ttm)
$1.19B
Revenue Growth
+21.32%
P/S Ratio
0.50
Revenue / Employee
$740,875
Employees
1,600
Market Cap
586.90M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
Dec 31, 2018 | 782.40M | 221.50M | 39.49% |
Dec 31, 2017 | 560.90M | 72.10M | 14.75% |
Dec 31, 2016 | 488.80M | -531.00K | -0.11% |
Dec 31, 2015 | 489.33M | 84.87M | 20.98% |
Dec 31, 2014 | 404.47M | 91.72M | 29.33% |
Dec 31, 2013 | 312.75M | 30.86M | 10.95% |
Dec 31, 2012 | 281.89M | 8.50M | 3.11% |
Dec 31, 2011 | 273.38M | -12.79M | -4.47% |
Dec 31, 2010 | 286.17M | 51.39M | 21.89% |
Dec 31, 2009 | 234.79M | 56.23M | 31.49% |
Dec 31, 2008 | 178.55M | -4.36M | -2.38% |
Dec 31, 2007 | 182.92M | 30.18M | 19.76% |
Dec 31, 2006 | 152.73M | 22.04M | 16.87% |
Dec 31, 2005 | 130.69M | 47.19M | 56.52% |
Dec 31, 2004 | 83.49M | 27.73M | 49.71% |
Dec 31, 2003 | 55.77M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Varex Imaging | 855.80M |
Orthofix Medical | 760.05M |
Pharming Group | 280.83M |
Surmodics | 142.96M |
Verve Therapeutics | 16.05M |
Allogene Therapeutics | 65.00K |
EBS News
- 13 days ago - Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan - GlobeNewsWire
- 13 days ago - Emergent, J&J settle COVID vaccine supply deal dispute - Reuters
- 19 days ago - Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? - Benzinga
- 19 days ago - Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products - GlobeNewsWire
- 19 days ago - Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day - GlobeNewsWire
- 2 months ago - Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024 - GlobeNewsWire